Evaluation of Remdesivir in Liver Functions Covid-19 Patients At Bhayangkara H.S Samsoeri Mertojoso Hospital Surabaya

Authors

  • Maria Angelia Yoshida Universitas Airlangga Author
  • Didik Hasmono Universitas Airlangga Author
  • Ruddy Hartono Bhayangkara Hospital H.S Samsoeri Mertojoso, Surabaya Author
  • Mohammad Subkhan Bhayangkara Hospital H.S Samsoeri Mertojoso, Surabaya Author

Keywords:

remdesivir, covid-19, hepatotoxicity

Abstract

Remdesivir is one of the effective anti-viral drugs used as a Covid-19 therapy at moderate, severe and critical degrees. Side effects that need to be considered in the use of remdesivir is hepatotoxicity. The active metabolite of remdesivir (GS-44152) is thought to play a role in mitochondrial damage in liver cells, inhibiting bile acid transport, and inducing oxidative stress. This study was conducted to evaluate the use of remdesivir associated with changes in liver function SGOT and SGPT. This study was retrospective observation of moderate, severe and critical COVID-19 patients receiving remdesivir with inclusion criteria of all inpatient medical records at Bhayangkara Hospital Surabaya for the period of August 2020-July 2021. The results showed that significant increase of liver enzymes occurred in SGPT (Pre 29 .50; Post 33.50) while in SGOT (Pre 33.00; Post 26.00), enzymes were significantly decreased. The decrease was greater in the SGPT (Pre 69.00; Post 47.00) and SGOT (Pre 56.00; Post 32.00) hepatoprotector groups. The use of remdesivir had no effect on liver function as indicated by an increase in SGPT value and a decrease in SGOT value, both of which were still in the normal range.

References

K. Renu, P. L. Prasanna, and A. V. Gopalakrishnan, “Coronaviruses pathogenesis, comorbidities and multi-organ damage – A review,” Life Sciences, no. January, p. 117839, 2020.

H. Chu et al., “Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study,” Lancet Microbe, no. January, pp. 19–21, 2020.

Z. Wang, W. Qiang, and H. Ke, “A Handbook of 2019-nCoV Pneumonia Control and Prevention,” Hubei Science and technology press, pp. 1–108, 2020.

C. Ceraolo and F. M. Giorgi, “Genomic Variance of the 2019-nCoV Coronavirus,” Journal of Medical Virology, vol. 92, no. 5. pp. 522–528, 2020. doi: 10.1002/jmv.25700.

M. Hoffmann, H. Kleine-Weber, N. Krüger, M. Müller, C. Drosten, and S. Pöhlmann, “The Novel Coronavirus 2019 (2019-nCoV) Uses the SARS-coronavirus Receptor ACE2 and the Cellular Protease TMPRSS2 for Entry into Target Cells,” bioRxiv, 2020, doi: 10.1101/2020.01.31.929042.

A. D. Nardo, M. S. May, E. D. Dixon, S. F. Lax, and M. Trauner, “Pathophysiological mechanisms of liver injury in COVID-19,” no. November, pp. 1–13, 2020, doi: 10.1111/liv.14730.

K. Yang, B. A. Howell, J. Y. Feng, D. Babusis, T. Cihlar, and S. Q. Siler, “Assessment of the Mechanism for Remdesivir-Associated Clinical ALT Elevations Using DILIsym Quantitative Systems Toxicology Modeling,” vol. 13, p. 2020, 2020.

E. Burhan et al., Pedoman tatalaksana COVID-19 Edisi 3 Desember 2020. 2020. [Online]. Available: https://www.papdi.or.id/download/983-pedoman-tatalaksana-covid-19-edisi-3-desember-2020

T. Haitao et al., “COVID-19 and Sex Differences: Mechanisms and Biomarkers,” MAYO CLINIC PROCEEDINGS, vol. 95, no. 1, pp. 2189–2203, 2020, [Online]. Available: http://www.akrabjuara.com/index.php/akrabjuara/article/view/919

M. J. Nasiri et al., “COVID-19 Clinical Characteristics, and Sex-Specific Risk of Mortality: Systematic Review and Meta-Analysis,” Frontiers in Medicine, vol. 7, no. July, pp. 1–10, 2020, doi: 10.3389/fmed.2020.00459.

PDPI, PERKI, PERDATIN, IDAI, and PAPDI, “Revisi Protokol Tatalaksana COVID?19,” 2021.

Yao Na et al., “Clinical characteristics and influencing factors of patients with novel coronavirus pneumonia combined with liver injury in Shaanxi region,” Chinese Journal of Hepatology, vol. 28(03), pp. 234–239, 2020, doi: doi: 10.3760/cma.j.cn501113-20200226-00070.

Y. J. Wong et al., “A systematic review and meta-analysis of the COVID-19 associated liver injury,” Annals of Hepatology, vol. 19, no. 6, pp. 627–634, 2020, doi: 10.1016/j.aohep.2020.08.064.

C. A. Philips et al., “Critically Ill COVID-19 Patient with Chronic Liver Disease - Insights into a Comprehensive Liver Intensive Care,” Journal of Clinical and Translational Hepatology, vol. 000, no. 000, pp. 000–000, 2021, doi: 10.14218/jcth.2020.00110.

J. G. Stoffolano, “Hematological and Biochemical Factors Predicting SARS Fatality in Taiwan,” Elsevier & Formosan Medical Association, pp. 439–450, 2006.

A. Delgado et al., “Characterisation of drug-induced liver injury in patients with covid-19 detected by a proactive pharmacovigilance program from laboratory signals,” Journal of Clinical Medicine, vol. 10, no. 19, 2021, doi: 10.3390/jcm10194432.

EMA, “Summary on Compassionate Use Remdesivir Gilead International Nonproprietary Name: Remdesivir,” European Medicines Agency, vol. 31, no. April, p. 41, 2020, [Online]. Available: https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf

A. Rezagholizadeh, S. Khiali, P. Sarbakhsh, and T. Entezari-Maleki, “Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis,” European Journal of Pharmacology, no. January, p. 173926, 2021.

J. H. Beigel et al., “Remdesivir for the Treatment of Covid-19 — Final Report,” New England Journal of Medicine, vol. 383, no. 19, pp. 1813–1826, 2020, doi: 10.1056/nejmoa2007764.

J. Grein et al., “Compassionate Use of Remdesivir for Patients with Severe Covid-19,” New England Journal of Medicine, vol. 382, no. 24, pp. 2327–2336, 2020, doi: 10.1056/nejmoa2007016

Downloads

Published

2024-11-14

Issue

Vol. 4 No. 5 (2022): J. Sains Kes.

Section

Articles

How to Cite

Evaluation of Remdesivir in Liver Functions Covid-19 Patients At Bhayangkara H.S Samsoeri Mertojoso Hospital Surabaya. (2024). Jurnal Sains Dan Kesehatan, 4(5), 459–463. https://jsk.ff.unmul.ac.id/index.php/JSK/article/view/535